Home »
Celcuity
Celcuity stock soars after breast cancer drug shows 76% risk reduction
Celcuity Inc. (NASDAQ: CELC) surged more than 100% in pre-market trading Monday after announcing historic results from its Phase 3 VIKTORIA-1 trial for gedatolisib, a targeted therapy for advanced breast cancer. Breakthrough results in hard-to-treat ... more
